The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. [PDF]
, 2017 Global tuberculosis incidence has declined marginally over the past decade, and tuberculosis remains out of control in several parts of the world including Africa and Asia.
Atre, Sachin R +41 more
core +1 more source
Treatment of Highly Drug-Resistant Pulmonary Tuberculosis [PDF]
, 2020 BACKGROUND Patients with highly drug-resistant forms of tuberculosis have limited treatment options and historically have had poor outcomes. METHODS In an open-label, single-group study in which follow-up is ongoing at three South African sites, we ...
Akkerman, Onno W +2 more
core +1 more source
Management of multidrug-resistant TB : novel treatments and their expansion to low resource settings [PDF]
, 2016 This article received no specific funding. JL is supported by the Wellcome Trust as a clinical PhD fellow [grant number 109105/Z/15/Z].Despite overall progress in global TB control, the rising burden ofmultidrug-resistant TB (MDR-TB) threatens to ...
Lewis, Joseph M., Sloan, Derek James
core +2 more sources
Fighting tuberculosis by drugs targeting nonreplicating Mycobacterium tuberculosis bacilli
International Journal of Mycobacteriology, 2017 Current tuberculosis (TB) treatment requires 6 months of combination therapy with isoniazid (INH), rifampin (RIF), pyrazinamide (PZA), and ethambutol for active TB and 9 months of INH or 3 months of rifapentine (RFP) + INH for latent TB.
Angelo Iacobino +4 more
doaj +1 more source
Estimated generic prices for novel treatments for drug resistant tuberculosis [PDF]
, 2016 Background: Estimated annual incidence of MDR-TB is 480,000, representing 5% of TB incidence, but 20% of mortality. Multiple drugs have recently been developed or re-purposed for the treatment of MDR-TB. Currently, treatment for MDR-TB costs thousands of
Cooke, GS +6 more
core +1 more source
Chiral Capillary Electrokinetic Chromatography: Principle and Applications, Detection and Identification, Design of Experiment, and Exploration of Chiral Recognition Using Molecular Modeling [PDF]
, 2021 This work reviews the literature of chiral capillary electrokinetic chromatography from January 2016 to March 2021. This is done to explore the state-of-the-art approach and recent developments carried out in this field.
Borges, Keyller Bastos +4 more
core +1 more source
CPT: Pharmacometrics &Systems Pharmacology, Volume 13, Issue 4, Page 673-685, April 2024.Abstract Tuberculosis (TB) is a life‐threatening infectious disease. The standard treatment is up to 90% effective; however, it requires the administration of four antibiotics (isoniazid, rifampicin, pyrazinamide, and ethambutol [HRZE]) over long time periods.
Maral Budak +7 more
wiley +1 more source
2016 Pipeline Report Tuberculosis Edition [PDF]
, 2016 Over the past decade, several new options for improving TB diagnosis have become available. The past year saw considerably more progress than the previous one. However, the reality of how most TB is diagnosed—or not—remains largely unchanged.
Erica Lessem +2 more
core
Accelerating development of new shorter TB treatment regimens in anticipation of a resurgence of multi-drug resistant TB due to the COVID-19 pandemic [PDF]
, 2021 The WHO 2020 global TB Report estimates that in 2019 there were an estimated 500,000 cases of multi-drug resistant TB (MDR-TB) of which only 186,772 MDR-TB cases were diagnosed, and positive treatment outcomes were achieved in 57% of them.
Galvin, J +5 more
core
Gene expression responses to anti-tuberculous drugs in a whole blood model. [PDF]
, 2020 BACKGROUND: There is a need for better tools to evaluate new or repurposed TB drugs. The whole blood bactericidal activity (WBA) assay has been advocated for this purpose.
De Sessions, Paola Florez +6 more
core +1 more source